Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies
Based on this modeling study, next-generation multitarget stool DNA was the only noninvasive screening test at guideline-endorsed interval and age-recommended ranges that was deemed efficient. Blood-based and multitarget stool RNA strategies were deemed not efficient for primary screening.
Authors
- John B. Kisiel (ORCID: https://orcid.org/0000-0002-3840-5324)
- Paul J. Limburg (ORCID: https://orcid.org/0000-0002-2428-5675)
- Derek W. Ebner (ORCID: https://orcid.org/0000-0003-0089-2507)
- Vahab Vahdat (ORCID: https://orcid.org/0000-0001-7831-7567)
- Ahmet Burak Ozbay (ORCID: https://orcid.org/0000-0002-8624-6313)
- A. Mark Fendrick (ORCID: https://orcid.org/0000-0002-7734-6742)
- Chris Estes (ORCID: https://orcid.org/0000-0002-2367-6535)
Institutions
- University of Michigan (US)
- Exact Sciences (United States) (US)
- Michigan Medicine (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1093/jnci/djaf209
- Citations
- 5
- Primary Topic
- Colorectal Cancer Screening and Detection
- Type
- article
- Field-Weighted Citation Impact
- 5.23